MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers
The prognosis of metastatic gastric cancer is poor. Despite the use of VEGF-, EGFR-, and HER2-targeting agents, prognosis is still poor in advanced gastric cancer. Although cancer immunotherapy responds well in some patients, clinical use is limited due to unanswered patients. For this reason, it is...
Saved in:
Main Author: | Ibrahim Halil Erdogdu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2019/4785098 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of the prognosis and lymph node metastasis between no tumor budding and low-grade tumor budding in T1 and T2 colorectal cancer
by: Jong Yoon Lee, et al.
Published: (2025-01-01) -
Predictive Value of Tumor Load in Breast Cancer Sentinel Lymph Nodes for Second Echelon Lymph Node Metastases
by: C. H. M. van Deurzen, et al.
Published: (2007-01-01) -
TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
by: Huanhuan Yin, et al.
Published: (2020-01-01) -
Prognostic Value of Metastatic Tumoral Caveolin-1 Expression in Patients with Resected Gastric Cancer
by: Der Sheng Sun, et al.
Published: (2017-01-01) -
Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth
by: Joanna Bandola-Simon, et al.
Published: (2025-01-01)